Inhibition of glucocorticoid-induced REDD1 expression by rapamycin in breast cancer cells
Introduction. Glucocorticoids are often used in combination therapy for breast cancer as an adjuvant to increase therapeutic effects of the main cytotoxic drug and to reduce side effects of chemotherapy. However, glucocorticoids can cause serious complications and trigger tumor progression. In the l...
Saved in:
Main Authors: | D. D. Grigorieva, E. M. Zhidkova, E. S. Lylova, D. V. Demina, K. I. Kirsanov, G. A. Belitsky, M. G. Yakubovskaya, E. A. Lesovaya |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2022-03-01
|
Series: | Успехи молекулярной онкологии |
Subjects: | |
Online Access: | https://umo.abvpress.ru/jour/article/view/415 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INHIBITION OF REDD1 EXPRESSION FOR THE REDUCTION OF GLUCOCORTICOID-INDUCED SIDE EFFECTS
by: E. S. Lylova, et al.
Published: (2020-12-01) -
Autophagy activation in breast cancer cells in vitro after the treatment with PI3K/AKT/mTOR inhibitors
by: D. D. Grigoreva, et al.
Published: (2022-12-01) -
Selective glucocorticoid receptor agonists as an alternative to glucocorticoids in the treatment of acute lymphoblastic leukemia: clinical response to glucocorticoids compared with molecular effects <i>in vitro</i>
by: O. A. Vlasova, et al.
Published: (2025-05-01) -
Molecular mechanisms of novel selective glucocorticoid receptor agonist action in breast cancer cells
by: E. M. Zhidkova, et al.
Published: (2024-10-01) -
COMPARATIVE ANALYSIS OF BIOLOGICAL EFFECTS OF SELECTIVE ACTIVATOR OF THE GLUCOCORTICOID RECEPTOR CPDA ON DIFFERENT SUBTYPES OF BREAST CANCER CELL LINES
by: E. M. Zhidkova, et al.
Published: (2017-12-01)